
|Articles|July 1, 2017
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque Psoriasis
In July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.
Advertisement
Links to PDF
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Day 2 Recap: South Beach Symposium 2026
2
Depth, Speed, and Durability: What Matters Most in Modern Clinical Trials
3
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
4
Doris Day, MD, on Redefining Anti-Aging in Dermatology
5











